Biotech Stock Bursting After Congressional Spending Bill

OMER stock is pacing for its best day since 2015

by Andrea Kramer

Published on Mar 22, 2018 at 10:02 AM

The shares of eye drug maker Omeros Corporation (NASDAQ:OMER) are skyrocketing this morning, thanks to the latest spending bill from Congress. Specific language in the package's Medicare reimbursement policy is beneficial to Omeros and "almost no other drug companies," according to STAT News (subscription required). Against this backdrop, OMER stock has soared 45% to trade at $16.89, on pace for its best day since August 2015.

Omeros shares are now knocking on the door of their 200-day moving average, which hasn't been conquered on a daily closing basis since mid-January. Prior to today, the stock was down 40% so far in 2018 -- and just touched an annual low of $8.36 on March 2 -- but has trimmed that deficit to 15%.

A short squeeze could add fuel to Omidria maker's fire, to boot. More than 18% of OMER stock's total float is dedicated to short interest, representing a week's worth of pent-up buying demand, at the security's average pace of trading. That's plenty of fuel for a short-covering rally.

Even before today's pop, though, OMER options traders were optimistic. On the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators bought to open more than four Omeros calls for every put during the past two weeks. However, some of that call buying -- particularly at out-of-the-money strikes -- could be attributable to short sellers seeking an options hedge.


a schaeffer's exclusive

PLAY TRENDS LIKE A PRO!

5 tips to leverage profits in this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.
Wall Street Reacts to Fed Decision, Trade Deal
Investors waited and reacted to the Fed decision and trade headlines
Sarepta Therapeutics Stock Eyes Best Day in 3 Years on FDA Reversal
SRPT is buzzing on the FDA's change of heart
The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.